Tumor-targeting therapy using gene-engineered anaerobic-nonpathogenic Bifidobacterium longum

Methods in Molecular Biology

Volumn 1409, Issue , 2016, Pages 49-60

  Taniguchi, Shun’ichiro ^a   Shimatani, Yuko ^a   Fujimori, Minoru ^a  

^a NONE

Author keywords

Anaerobic; Bifidobacterium longum; Cancer therapy; Carrier; DDS; Hypoxia; Nonpathogenic; Oxygen; Tumor targeting

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL;

ANAEROBIC BACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIFIDOBACTERIUM LONGUM; BREAST CARCINOMA; BREAST TUMOR; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HYPOXIA; MALE; MOUSE; NONHUMAN; RAT; SOLID TUMOR; ANIMAL; BIFIDOBACTERIUM; DISEASE MODEL; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; ISOGRAFT; METABOLISM; NEOPLASMS; OXYGEN CONSUMPTION; PATHOLOGY;

ANIMALS; BIFIDOBACTERIUM; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; HUMANS; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASMS; OXYGEN CONSUMPTION; RATS; TRANSPLANTATION, ISOGENEIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957608208     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3515-4_5     Document Type: Chapter

References (14)

1. Kimura NT, Taniguchi S, Aoki K, Baba T (1980) Selective localization and growth of Bifi dobacterium bifi dom in mouse tumors following intraveneous administration. Cancer Res 40:2061-2068
2. Taniguchi S, Fujimori M, Sasaki T, Tsutsui H, Shimatani Y, Seki K, Amano J (2010) Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci 101:1925-1932
3. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437
4. Sullivan R, Graham CH (2007) Hypoxiadriven selection of the metastatic phenotype. Cancer Metastasis Rev 26:319-331
5. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S (2001) Bifi dobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66:165-170
6. Nakamura T, Sasaki T, Fujimori M, Yazawa K, Kano Y, Amano J, Taniguchi S (2002) Cloned cytosine deaminase gene expression of Bifi dobacterium longum and application to enzyme/ pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem 66:2362-2366
7. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S (2000) Bifi dobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 7:269-274
8. Sasaki T, Fujimori M, Hamaji Y, Hama Y, Ito K, Amano J, Taniguchi S (2006) Genetically engineered Bifi dobacterium longum for tumortargeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci 97:649-657
9. Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10:785-794
10. Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P et al (2008) Effects of nonpathogenic gramnegative bacterium Vitreoscilla fi liformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 159:1357-1363
11. He X, Lux R, Kuramitsu HK, Anderson MH, Shi W (2009) Achieving probiotic effects via modulating oral microbial ecology. Adv Dent Res 21:53-56
12. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ et al (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20:142-152
13. Wei MQ, Mengesha A, Good D, Anne J (2008) Bacterial targeted tumour therapy dawn of a new era. Cancer Lett 259:16-27
14. Takeuchi A, Matsumura H, Kano Y (2002) Cloning and expression in Escherichia coli of a gene, hup , encoding the histone-like protein HU of Bifi dobacterium longum . Biosci Biotechnol Biochem 66:598-603